Vigna Law Group highlights Depo-Provera bellwether cases in California

Vigna Law Group says it represents four defense bellwether selections and dozens of women in California litigation over Depo-Provera use before 2002. The firm is seeking discovery tied to meningioma reports as the broader litigation tests safety-signal and regulatory issues.

Why it matters: - The California bellwether trials could help shape the value and direction of the wider Depo-Provera litigation. - The cases center on allegations that Depo-Provera may be linked to a dose-dependent increase in meningiomas. - The discovery fight also raises questions about how safety signals were reviewed and when Pfizer knew what about the risk.

What happened: - Vigna Law Group said it represents four defense bellwether selections in the California consolidated litigation involving women prescribed Depo-Provera before 2002. - The firm also said it represents dozens of women who received Depo-Provera between 1992 and 2002. - Dr. Greg Vigna said the firm is involved in the upcoming California bellwether trials. - The California cases are identified as Case No. 26CV189984, Case No. 26CV179081, Case No. 26CV178116 and Case No. 26CV179212. - Vigna said the firm has cases filed in Minnesota, Connecticut, California, New Hampshire, Wisconsin, Washington and in the multidistrict litigation with Ben Martin Law Group.

The details: - The litigation includes allegations concerning Pfizer's conduct from the 1950s through the 1990s. - Vigna said the company requires signal analysis for newly described complaints. - The firm said it is reviewing issues related to signal analysis as part of its representation. - Through California JCCP discovery, the firm has requested emails and other documents relating to meningioma reports submitted to Pfizer. - The litigation also includes allegations about whether Pfizer's conduct was consistent with applicable regulatory and good clinical practice requirements. - The press release includes a link to the firm's meningioma resection practice area page. - The release also points readers to a Therapeutic Advances in Drug Safety article on signal detection and communications in pharmacovigilance published in 2020. - The release promotes a seven-minute educational episode on Justice with Dr. V about meningiomas and Depo-Provera. - The release directs readers to watch Justice with Dr. V on TikTok for more information about Depo-Provera.

Between the lines: - The firm is using the bellwether process to spotlight broader questions about drug safety monitoring and corporate document discovery. - The focus on meningioma reports suggests the litigation is turning on both medical causation and the timing of internal safety reviews. - The wide geographic spread of cases signals a growing national dispute, not just a California matter.

What's next: - The upcoming California bellwether trials are likely to test plaintiff and defense themes before later settlement or trial strategy decisions. - Discovery in the California JCCP will continue to shape what internal Pfizer documents may enter the record. - The outcome may influence other Depo-Provera cases already filed in multiple states and in multidistrict litigation. - Vigna Law Group also lists offices in Los Angeles, San Jose, Modesto, Roseville, San Diego and Middletown, Connecticut.